No significant difference between Dabigatran etexilate and enoxaparin in VTE occurrence
How to Cite
OrthoEvidence. No significant difference between Dabigatran etexilate and enoxaparin in VTE occurrence . ACE Report. 2013;2(7):161. Available from: https://myorthoevidene.com/AceReport/Report/740
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialLancet. 2007 Sep 15;370(9591):949-56
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
3494 patients undergoing total hip replacement were randomized to either receive 220mg of Dabigatran etexilate, 150mg of Dabigatran etexilate, or enoxaparin. The results following the treatment period (33 days) indicate that there were no significant differences between all three groups in terms of reducing the risk of major venous thromboembolism and all-cause mortality. In addition the safety ou...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE